Eric R. Olson - Jul 17, 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Chief Scientific Officer
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Stock symbol: SYRS
Transactions as of: Jul 17, 2023
Transactions value $: -$2,412
Form type: 4
Date filed: 7/18/2023, 08:27 PM
Previous filing: Apr 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Sale	-$2.41K	-689	-9.37%	$3.50	6.66K	Jul 17, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 31, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.